Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05665283
- Locations
- 🇺🇸
ICON - Early Development Services, Lenexa, Kansas, United States
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05393466
Expanded Access to Ensartinib for Participants With ALK+ NSCLC
- Conditions
- Non-Small Cell Lung CancerALK Gene Rearrangement Positive
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Xcovery Holdings, Inc.
- Registration Number
- NCT04146571
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT02767804
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University Cancer & Blood Center, Athens, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
- Conditions
- Advanced Solid TumorsNon-small Cell Lung Cancer
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Xcovery Holdings, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01625234
- Locations
- 🇺🇸
City of Hope National Med Ctr, Duarte, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States